27777972|t|Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy
27777972|a|Current antiangiogenesis therapy relies on inhibiting newly developed immature tumor blood vessels and starving tumor cells. This strategy has shown transient and modest efficacy. Here, we report a better approach to target cancer -associated endothelial cells (ECs), reverse permeability and leakiness of tumor blood vessels, and improve delivery of chemotherapeutic agents to the tumor. First, we identified deregulated microRNAs (miRs) from patient -derived cancer -associated ECs. Silencing these miRs led to decreased vascular permeability and increased maturation of blood vessels. Next, we screened a thioaptamer (TA) library to identify TAs selective for tumor -associated ECs. An annexin A2 - targeted TA was identified and used for delivery of miR106b-5p and miR30c-5p inhibitors, resulting in vascular maturation and antitumor effects without inducing hypoxia. These findings could have implications for improving vascular - targeted therapy.
27777972	0	9	Improving	T080	C1272745
27777972	10	29	vascular maturation	T042	C1621275
27777972	36	50	noncoding RNAs	T114	C0887909
27777972	61	70	antitumor	T080	C2986475
27777972	71	77	effect	T080	C1280500
27777972	81	93	chemotherapy	T061	C3665472
27777972	102	126	antiangiogenesis therapy	T061	C0281318
27777972	137	147	inhibiting	T052	C3463820
27777972	164	172	immature	T080	C0205252
27777972	173	192	tumor blood vessels	T191	C0027668
27777972	206	217	tumor cells	T025	C0597032
27777972	243	252	transient	UnknownType	C0151203
27777972	264	272	efficacy	T080	C1280519
27777972	311	317	target	T169	C1521840
27777972	318	324	cancer	T191	C0006826
27777972	337	354	endothelial cells	T025	C0225336
27777972	356	359	ECs	T025	C0225336
27777972	362	369	reverse	T169	C1555029
27777972	370	382	permeability	T070	C0031164
27777972	387	396	leakiness	T169	C0332234
27777972	400	419	tumor blood vessels	T191	C0027668
27777972	433	441	delivery	T169	C1705822
27777972	445	468	chemotherapeutic agents	T121	C0729502
27777972	476	481	tumor	T191	C0027651
27777972	504	515	deregulated	T052	C1880287
27777972	516	525	microRNAs	T114,T123	C1101610
27777972	527	531	miRs	T114,T123	C1101610
27777972	538	545	patient	T101	C0030705
27777972	555	561	cancer	T191	C0006826
27777972	574	577	ECs	T025	C0225336
27777972	579	588	Silencing	T045	C0598496
27777972	595	599	miRs	T114,T123	C1101610
27777972	607	616	decreased	T081	C0205216
27777972	617	638	vascular permeability	T042	C0162337
27777972	643	652	increased	T081	C0205217
27777972	653	680	maturation of blood vessels	T042	C1621275
27777972	691	699	screened	T058	C1710032
27777972	702	713	thioaptamer	T114	C0599013
27777972	715	717	TA	T114	C0599013
27777972	719	726	library	T028,T114	C0017272
27777972	739	742	TAs	T114	C0599013
27777972	757	762	tumor	T191	C0027651
27777972	775	778	ECs	T025	C0225336
27777972	783	793	annexin A2	T116,T123	C0103404
27777972	796	804	targeted	T169	C1521840
27777972	805	807	TA	T114	C0599013
27777972	836	844	delivery	T169	C1705822
27777972	848	858	miR106b-5p	T114,T123	C1101610
27777972	863	872	miR30c-5p	T114,T123	C1101610
27777972	873	883	inhibitors	T080	C1999216
27777972	898	906	vascular	T023	C0005847
27777972	907	917	maturation	T040	C0678723
27777972	922	931	antitumor	T080	C2986475
27777972	932	939	effects	T080	C1280500
27777972	957	964	hypoxia	T046	C0242184
27777972	972	980	findings	T033	C0243095
27777972	1019	1027	vascular	T023	C0005847
27777972	1030	1038	targeted	T169	C1521840
27777972	1039	1046	therapy	T169	C0039798